A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical trial to determine the maximum tolerated dose (MTD) of the
polo-like kinase-1 inhibitor volasertib which can be safely combined with idarubicin plus
cytarabine induction chemotherapy for previously untreated patients with acute myeloid
leukemia. (AML).